Literature DB >> 16103419

An automated multistep high-throughput screening assay for the identification of lead inhibitors of the inducible enzyme mPGES-1.

Frédéric Massé1, Sébastien Guiral, Louis-Jacques Fortin, Elizabeth Cauchon, Diane Ethier, Jocelyne Guay, Christine Brideau.   

Abstract

Prostaglandin E2 synthase (mPGES-1), the enzyme which catalyzes the synthesis of PGE2, is induced during the inflammatory response. For this reason, mPGES-1 could be a potential therapeutic target. A high-throughput screening assay was developed to identify potential inhibitors of mPGES-1. The assay consisted of a 30-s mPGES-1 enzymatic reaction followed by the detection of PGE2 by enzyme immunoassay (EIA). The enzymatic reaction was performed in a batch mode because the instability of the substrate (10 min) limited the number of plates assayed within a working day. The detection of the product by EIA was performed on 3 instruments requiring 14 different steps for complete automation. The authors describe here the optimization and implementation of a 2-part assay on a Thermo CRS robotic system. More than 315,000 compounds were tested, and a hit rate of 0.84% was obtained for this assay. Although the entire assay required multiple steps, the assay was successfully miniaturized and automated for a high-throughput screening campaign.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103419     DOI: 10.1177/1087057105276083

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  3 in total

1.  Targeting microsomal prostaglandin E synthase 1 to develop drugs treating the inflammatory diseases.

Authors:  Qian Wang; Yuanyuan Li; Mengying Wu; Songming Huang; Aihua Zhang; Yue Zhang; Zhanjun Jia
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

Review 2.  Identification and development of mPGES-1 inhibitors: where we are at?

Authors:  Hui-Hua Chang; Emmanuelle J Meuillet
Journal:  Future Med Chem       Date:  2011-11       Impact factor: 3.808

3.  Engineering 'Enzymelink' for screening lead compounds to inhibit mPGES-1 while maintaining prostacyclin synthase activity.

Authors:  Diana T Ruan; Nanhong Tang; Hironari Akasaka; Renzhong Lu; Ke-He Ruan
Journal:  Future Med Chem       Date:  2021-06-03       Impact factor: 4.767

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.